Skip to main content

Table 3 Observed median survival, by indication, sex, type of diagnosis, age at diagnosis, and year of diagnosis

From: Overall survival of individuals with metastatic cancer in Sweden: a nationwide study

Patient characteristics

Median survival (months, 95% CI)

Metastatic breast cancer

Metastatic non-small cell lung cancer

Metastatic colorectal cancer

Metastatic ovarian cancer

Metastatic malignant melanoma

Type of diagnosis

De novo

20.8 (19.6, 22.8)

5.5 (5.3, 5.6)

13.8 (13.3, 14.2)

NA

12.7 (9.9, 15.3)

Recurrence

19.8 (19.3, 20.5)

4.16 (4, 4.4)

11.7 (11.3, 12.2)

NA

7 (6.5, 7.6)

Age at diagnosis

< 50 y

30.9 (29.1, 33.0)

8.7 (7.8, 10.7)

21.5 (19.9, 23.2)

33.3 (26.2, 40.7)

11.6 (10.2, 12.9)

50 – 59 y

27.6 (25.9, 29.5)

6.43 (6.2, 6.9)

22.5 (21.1, 24)

29.2 (25.8, 35.1)

11.2 (9.7, 13.1)

60 – 69 y

23.9 (22.3, 25.3)

5.8 (5.6, 6.0)

18.4 (17.6, 19.1)

24.1 (21.4, 27.1)

9.1 (7.8, 10.4)

70 – 79 y

18.8 (17.5, 19.9)

4.59 (4.4, 4.8)

11.7 (11.2, 12.2)

21.2 (18.3, 24.1)

6.2 (5.2, 7.3)

80 + y

7.9 (7.3, 8.6)

3.5 (3.3, 3.8)

5 (4.7, 5.3)

11.6 (7.8, 14.7)

3.2 (2.9, 3.8)

Year of diagnosis

2005 – 2009

16.4 (15.4, 17.4)

4.5 (4.3, 4.7)

10.5 (10.2, 11.0)

19.2 (17.1, 22.4)

5.4 (4.8, 6.3)

2010 – 2014

20.3 (19.4, 21.2)

5.2 (4.9, 5.4)

13.3 (12.8, 13.8)

22.6 (20.1, 24.7)

6.1 (5.6, 7.2)

2015 – 2018

26.2 (24.8, 28.2)

6 (5.7, 6.3)

15.7 (15.0, 16.5)

31.5 (26.5, 35.4)

11.5 (10.5, 13.5)

Sex

Men

NA

4.8 (4.6, 4.9)

13.8 (13.3, 14.2)

NA

6.8 (6.2, 7.6)

Women

NA

5.7 (5.5, 5.9)

11.7 (11.3, 12.2)

NA

8.2 (7.3, 9.6)

  1. CI Confidence interval, y year